Figures computed from official regulatory filings — .
Analysttarget 11.5 USD (+546%) · consensus 4.75/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 1.75% · institutions 34.71% · short 2.0% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Cellectar Biosciences, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
48 buys37 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Loren Stefan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Chanan-Khan Asher | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CARUSO JAMES Vtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kolean Chad J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Longcor Jarrodtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| NEIS JOHNtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| DRISCOLL FREDERICK Wtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Swirsky Douglas Jtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gu Andrew | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| CARUSO JAMES Vtrack record | BuyD (derivative) | $260.4 | SEC |
| Longcor Jarrodtrack record | Buy | $25K | conv 50 | SEC |
| CARUSO JAMES Vtrack record | Buy | $25K | conv 54 | SEC |
| Longcor Jarrodtrack record | BuyD (derivative) | $260.4 | SEC |
| NEIS JOHNtrack record | Sell | $732.6 | SEC |
| Kolean Chad J | BuyD (derivative) | $50 | ClusterFirst in 12mo | SEC |
| Longcor Jarrodtrack record | Buy | $49.9K | conv 76Cluster | SEC |
| Longcor Jarrodtrack record | BuyD (derivative) | $100 | Cluster | SEC |
| CARUSO JAMES Vtrack record | BuyD (derivative) | $100 | ClusterFirst in 12mo | SEC |
| CARUSO JAMES Vtrack record | Buy | $49.9K | conv 85ClusterFirst in 12mo | SEC |
| Kolean Chad J | Buy | $25K | conv 98ClusterFirst in 12mo | SEC |
| Longcor Jarrodtrack record | Buy | $8.4K | conv 63First in 12mo | SEC |
| Chanan-Khan Asher | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| NEIS JOHNtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Loren Stefan | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kolean Chad J | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |